ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: By exposing K562 cells to therapeutic tyrosine inhibitors57 we established that cell death is dose dependent and therefore K562 represents a good model for CML therapy with BCR-ABL as a survival factor (Supplementary Fig. 21).